Premium
Recombinant factor VIIa prophylaxis in a patient with severe congenital factor VII deficiency
Author(s) -
Tcheng W. Y.,
Donkin J.,
Konzal S.,
Wong W.Y.
Publication year - 2004
Publication title -
haemophilia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.213
H-Index - 92
eISSN - 1365-2516
pISSN - 1351-8216
DOI - 10.1111/j.1365-2516.2004.00885.x
Subject(s) - medicine , recombinant factor viia , factor viia , prophylactic treatment , regimen , surgery , factor vii , coagulation , tissue factor
Summary. Use of recombinant factor VIIa (rFVIIa, NovoSeven ® ) in patients with congenital FVII deficiency has been reported for the prophylactic management of surgical bleeding and for the treatment of acute bleeding episodes. Because of its short half‐life, the use of rFVIIa on a regular prophylactic regimen has not been routinely adopted. In this report, we describe our successful experience with rFVIIa prophylaxis in preventing recurrent target joint bleeding in a severely FVII‐deficient adolescent.